Ken Fisher’s Viridian Therapeutics VRDN Stock Holding History

Ken Fisher’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$32.2M	Sell	1,750,850 -17,445	-1%	-$281K	0.01%	294
2026 Q1	$34.6M	Sell	1,768,295 -11,989	-0.7%	-$356K	0.01%	272
2025 Q4	$55.4M	Buy	1,780,284 +579,058	+48%	+$15.9M	0.02%	223
2025 Q3	$25.9M	Buy	1,201,226 +691,267	+136%	+$12.5M	0.01%	290
2025 Q2	$7.13M	Sell	509,959 -27,065	-5%	-$367K	﹤0.01%	438
2025 Q1	$7.24M	Buy	537,024 +18,997	+4%	+$324K	﹤0.01%	452
2024 Q4	$9.93M	Buy	518,027 +23,103	+5%	+$502K	﹤0.01%	432
2024 Q3	$11.3M	Buy	494,924 +99,427	+25%	+$1.63M	﹤0.01%	407
2024 Q2	$5.15M	Buy	395,497 +6,410	+2%	+$88.7K	﹤0.01%	486
2024 Q1	$6.81M	Buy	+389,087	New	+$7.54M	﹤0.01%	464

Other funds holding VRDN

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

FMI

F/M Investments Washington, District of Columbia $1.97B AUM 30.33% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

JSSH

J. Safra Sarasin Holding $6.97B AUM 32.91% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

FISPB

Fideuram - Intesa Sanpaolo Private Banking Turin $3.33B AUM

Ken Fisher's VRDN Position: Q2 2026 in Review

Ken Fisher reduced its Viridian Therapeutics (VRDN) stake by 0.99% in Q2 2026, selling an estimated $281K and leaving 1,750,850 shares worth $32.2M. The position accounts for 0.01% of the portfolio, ranked #294.

Ken Fisher first reported a position in VRDN in Q1 2024 and has held it in 10 quarters since. The position peaked at $55.4M in Q4 2025. 44 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

Ken Fisher held 1,750,850 shares of Viridian Therapeutics worth $32.2M as of Q2 2026.
Ken Fisher sold 17,445 Viridian Therapeutics shares in Q2 2026, an estimated $281K.
Viridian Therapeutics made up 0.01% of Ken Fisher's portfolio in Q2 2026, its #294 holding.
Ken Fisher first reported a position in Viridian Therapeutics in Q1 2024 and has held it in 10 quarters since.
Ken Fisher's Viridian Therapeutics position peaked at $55.4M in Q4 2025.
44 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Fisher Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.